BI 425809

Drug Profile

BI 425809

Alternative Names: BI-425809

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders

Most Recent Events

  • 03 Oct 2016 Boehringer Ingelheim suspends enrolment in a phase II trial for Cognition disorders (in patients with Schizophrenia) in Austria, Poland, Spain, USA, Japan, Canada, United Kingdom, Italy, Germany, South Korea and Taiwan (PO) (NCT02832037)
  • 03 Oct 2016 Boehringer Ingelheim suspends enrolment in a phase II trial for Cognition disorders (in patients with Alzheimer's disease) in Finland, Norway, USA, Austria, Hungary, Canada, France, United Kingdom, Italy, Japan, Spain, Greece and Germany (PO) (NCT02788513)
  • 01 Aug 2016 Phase-II clinical trials in Cognition disorders in Finland, Hungary, Greece (PO) (NCT02788513)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top